YOKO FUKUDA M.D. NPI 1568622801

NPI Details

Yoko Fukuda, M.D. is a hematology and oncology internal medicine in Portsmouth, NH with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Yoko Fukuda, M.D. NPI is 1568622801. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

155 BORTHWICK AVE STE C
PORTSMOUTH, NH
ZIP 03801-156
Phone: (603) 828-0100
Fax: (603) 828-0111

The NPI 1568622801 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Administration of influenza virus vaccine (HCPCS:G0008)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)

The enumeration date for this NPI number is 6/10/2008 and was last updated on 4/28/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: